AbbVie

News

Billions up for grabs as EU patent on AbbVie's Humira expire...

The patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a host of cheaper biosimilars to hit the market.

News

Sandoz free to launch Humira biosimilar following AbbVie dea...

Novartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab) in Europe this year after the two companies settled intellectual

News

Humira developer Winter among Nobel chemistry prize winners

A scientist who pioneered the technology used to discover the biggest selling drug in the world, AbbVie’s Humira, was among a trio who received this year’s Nobel Prize in Chemistry.

News

Mylan and Fujifilm join Humira bunfight as fifth EU biosimil...

Mylan and Fujifilm Kyowa Kirin Biologics have got their Humira biosimilar approved in Europe – the fifth cut-price competitor approved ahead of patent expiry on AbbVie’s inflammatory diseas

News

AbbVie braces for impact of Humira biosimilars in Europe

AbbVie looks set to lose several billion dollars in revenue from Humira, as its soon to expire European patent presents healthcare providers with a major cost-saving opportunity for a biosi

News

AbbVie takes option on Argenx's cancer immunotherapy

ARGX-115 is still in preclinical development

Billions up for grabs as EU patent on AbbVie's Humira expire...

Sandoz free to launch Humira biosimilar following AbbVie dea...

Humira developer Winter among Nobel chemistry prize winners

Mylan and Fujifilm join Humira bunfight as fifth EU biosimil...

AbbVie braces for impact of Humira biosimilars in Europe

AbbVie takes option on Argenx's cancer immunotherapy

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks